J&J’s 6% slide on an imperfect quarter is a gift to prospective buyers

by admin 0 Comments

Earnings
Share on Facebook
Share on Twitter
Share on Pinterest
Share on LinkedIn

J&J's pharmaceutical division is humming along, and the MedTech problems should be temporary.

Read the original report.

Share on Facebook
Share on Twitter
Share on Pinterest
Share on LinkedIn

Articles You May Like

JetBlue raises bag fees for third time in a year as fuel costs bite
CVS to split off drugstore business in major breakup of healthcare giant; shares fall 10%
Cruise companies aim to keep fuel costs down. Their strategies for doing so differ
Tesla to wind down Cybertruck production in Texas next year to ramp Cybercab, Musk says
I bonds now pay 5.51% — but there are trade-offs. What to know before buying

Leave a Reply

Your email address will not be published. Required fields are marked *